Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Malaria vaccine - Mymetics

Drug Profile

Malaria vaccine - Mymetics

Alternative Names: PEV 1002A; PEV 301; PEV 302; PEV3; PEV3A

Latest Information Update: 20 Dec 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pevion Biotech
  • Developer Mymetics Corporation; Swiss Tropical Institute
  • Class Antimalarials; Parasitic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Malaria

Highest Development Phases

  • Phase I Malaria

Most Recent Events

  • 20 Dec 2018 Clinical development is ongoing in Tanzania (Mymetics website - December 2018)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Malaria in Switzerland (Parenteral, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Malaria(In adolescents, In children) in Tanzania (Parenteral, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top